JP2005525322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525322A5 JP2005525322A5 JP2003564040A JP2003564040A JP2005525322A5 JP 2005525322 A5 JP2005525322 A5 JP 2005525322A5 JP 2003564040 A JP2003564040 A JP 2003564040A JP 2003564040 A JP2003564040 A JP 2003564040A JP 2005525322 A5 JP2005525322 A5 JP 2005525322A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- general formula
- different
- methyl
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- -1 hydroxy, methyl Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 229940006460 bromide ion Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010040741 Sinus bradycardia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000013312 porous aromatic framework Substances 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 230000001515 vagal effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10203753A DE10203753A1 (de) | 2002-01-31 | 2002-01-31 | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| PCT/EP2003/000532 WO2003064417A1 (de) | 2002-01-31 | 2003-01-21 | Xanthencarbonsäureester des tropenols und scopins als m3-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525322A JP2005525322A (ja) | 2005-08-25 |
| JP2005525322A5 true JP2005525322A5 (enExample) | 2006-03-09 |
| JP4554936B2 JP4554936B2 (ja) | 2010-09-29 |
Family
ID=27588164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564040A Expired - Lifetime JP4554936B2 (ja) | 2002-01-31 | 2003-01-21 | Ｍ３アンタゴニストとしてのトロペノール及びスコピンのキサンテンカルボン酸エステル、その製造方法及び薬物としてのその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1472249B1 (enExample) |
| JP (1) | JP4554936B2 (enExample) |
| AT (1) | ATE335738T1 (enExample) |
| CA (1) | CA2471578C (enExample) |
| DE (2) | DE10203753A1 (enExample) |
| ES (1) | ES2269977T3 (enExample) |
| WO (1) | WO2003064417A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10230751A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| EP1651224B1 (en) * | 2003-07-31 | 2011-10-05 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE102004001607A1 (de) * | 2004-01-09 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern |
| WO2005079794A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and pegsunercept |
| US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| ES2322148T3 (es) * | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| WO2006087316A1 (en) * | 2005-02-16 | 2006-08-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising anticholinergics and etiprednol |
| EP1858554A2 (en) * | 2005-03-09 | 2007-11-28 | Boehringer Ingelheim International GmbH | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
| CA2609429A1 (en) * | 2005-05-31 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| MX2008001976A (es) | 2005-08-15 | 2008-03-25 | Boehringer Ingelheim Int | Procedimiento para la preparacion de betamimeticos. |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| ES2360963T3 (es) | 2006-08-07 | 2011-06-10 | Boehringer Ingelheim International Gmbh | Combinaciones de fármacos para el tratamiento de enfermedades de las vías respiratorias. |
| UY30550A1 (es) | 2006-08-22 | 2008-03-31 | Boehringer Ingelheim Int | Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos |
| ES2569359T3 (es) | 2007-07-06 | 2016-05-10 | Vectura Delivery Devices Limited | Inhalador |
| US20100234411A1 (en) * | 2007-07-18 | 2010-09-16 | Boehringer Ingelheim Intermational Gmbh | New Combination for the Treatment of Respiratory Diseases |
| EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
| EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| EP2093219A1 (de) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel |
| GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3127373A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| DE10050994A1 (de) * | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
-
2002
- 2002-01-31 DE DE10203753A patent/DE10203753A1/de not_active Withdrawn
-
2003
- 2003-01-21 CA CA2471578A patent/CA2471578C/en not_active Expired - Fee Related
- 2003-01-21 WO PCT/EP2003/000532 patent/WO2003064417A1/de not_active Ceased
- 2003-01-21 AT AT03704440T patent/ATE335738T1/de active
- 2003-01-21 DE DE50304569T patent/DE50304569D1/de not_active Expired - Lifetime
- 2003-01-21 ES ES03704440T patent/ES2269977T3/es not_active Expired - Lifetime
- 2003-01-21 JP JP2003564040A patent/JP4554936B2/ja not_active Expired - Lifetime
- 2003-01-21 EP EP03704440A patent/EP1472249B1/de not_active Expired - Lifetime